$PAVM
PAVmed Inc. Stock $pavm

$pavm Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011172 Filed on March 25, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.000M	$1.049M	$2.500M
YoY Change	124.22%	836.61%	563.13%
Cost Of Revenue	$1.744M	$1.611M	$6.420M
YoY Change	29.57%	-0.43%	77.64%
Gross Profit	-$744.0K	-$562.0K	-$3.920M
YoY Change	-17.33%	-62.68%	21.1%
Gross Profit Margin	-74.4%	-53.57%	-156.8%
Selling, General & Admin	$10.99M	$11.72M	$48.53M
YoY Change	-24.51%	-25.9%	-19.6%
% of Gross Profit
Research & Development	$1.941M	$3.595M	$14.28M
YoY Change	-56.27%	-46.13%	-44.12%
% of Gross Profit
Depreciation & Amortization	$586.0K	$722.0K	$2.932M
YoY Change	-19.39%	-0.55%	19.33%
% of Gross Profit
Operating Expenses	$12.93M	$15.82M	$62.81M
YoY Change	-31.93%	-31.21%	-26.89%
Operating Profit	-$14.04M	-$16.38M	-$68.80M
YoY Change	-31.2%	-33.14%	-24.34%
Interest Expense	-$2.107M	-$275.0K	-$6.500M
YoY Change	91.2%	-213.17%	155.4%
% of Operating Profit
Other Income/Expense, Net	-$4.476M	$0.00	-$10.47M
YoY Change	146.88%		-14.97%
Pretax Income	-$18.51M	-$17.41M	-$79.26M
YoY Change	-16.67%	-29.16%	-23.22%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$15.21M	-$15.91M	-$64.18M
YoY Change	-15.16%	-22.54%	-27.88%
Net Earnings / Revenue	-1521.2%	-1516.21%	-2567.0%
Basic Earnings Per Share	-$2.62		-$9.16
Diluted Earnings Per Share	-$2.62	-$1.98	-$9.16
COMMON SHARES
Basic Shares Outstanding	9.172M shares	120.8M shares	7.232M shares
Diluted Shares Outstanding	8.695M shares		7.232M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.88M	$22.31M	$22.31M
YoY Change	-47.2%	-47.81%	-47.81%
Cash & Equivalents	$25.54M	$19.64M	$2.672M
Short-Term Investments
Other Short-Term Assets	$1.214M	$1.848M	$1.848M
YoY Change	20.92%	59.31%	59.31%
Inventory	$410.0K	$278.0K	$278.0K
Prepaid Expenses
Receivables	$67.00K	$61.00K	$61.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$29.57M	$24.50M	$24.50M
YoY Change	-45.07%	-44.23%	-44.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.595M	$1.783M	$6.050M
YoY Change	-29.27%	-27.25%	10.24%
Goodwill
YoY Change
Intangibles	$1.052M	$1.424M
YoY Change	-64.22%	-58.66%
Long-Term Investments
YoY Change
Other Assets	$1.147M	$1.147M	$1.147M
YoY Change	6.3%	2.32%	2.32%
Total Long-Term Assets	$7.680M	$8.621M	$8.621M
YoY Change	-32.9%	-14.25%	-14.25%
TOTAL ASSETS
Total Short-Term Assets	$29.57M	$24.50M	$24.50M
Total Long-Term Assets	$7.680M	$8.621M	$8.621M
Total Assets	$37.25M	$33.12M	$33.12M
YoY Change	-42.94%	-38.65%	-38.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.485M	$1.786M	$1.786M
YoY Change	18.04%	-33.95%	-33.95%
Accrued Expenses	$6.657M	$6.626M	$7.414M
YoY Change	78.76%	78.84%	100.11%
Deferred Revenue
YoY Change
Short-Term Debt	$45.54M	$44.20M	$44.20M
YoY Change	-0.05%	27.04%	27.04%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$55.02M	$54.18M	$54.18M
YoY Change	8.84%	31.5%	31.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.814M	$2.960M	$2.960M
YoY Change	-28.51%	60.35%	60.35%
Total Long-Term Liabilities	$2.814M	$2.960M	$2.960M
YoY Change	-28.51%	60.35%	60.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$55.02M	$54.18M	$54.18M
Total Long-Term Liabilities	$2.814M	$2.960M	$2.960M
Total Liabilities	$57.83M	$57.14M	$86.95M
YoY Change	6.14%	32.73%	36.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$309.7M	-$294.4M
YoY Change	25.82%	29.04%
Common Stock	$9.000K	$9.000K
YoY Change	-91.09%	-90.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$68.78M	-$53.83M	-$53.83M
YoY Change
Total Liabilities & Shareholders Equity	$37.25M	$33.12M	$33.12M
YoY Change	-42.94%	-38.65%	-38.65%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$15.21M	-$15.91M	-$64.18M
YoY Change	-15.16%	-22.54%	-27.88%
Depreciation, Depletion And Amortization	$586.0K	$722.0K	$2.932M
YoY Change	-19.39%	-0.55%	19.33%
Cash From Operating Activities	-$13.10M	-$11.88M	-$52.00M
YoY Change	-19.57%	-29.41%	-26.75%
INVESTING ACTIVITIES
Capital Expenditures	$42.00K	$182.0K	$242.0K
YoY Change	61.54%	-38.93%	-84.29%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$1.000M
YoY Change	-100.0%		-131.25%
Cash From Investing Activities	-$42.00K	-$182.0K	$758.0K
YoY Change	-104.31%	-38.93%	-115.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.533M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$19.05M	5.283M	$31.17M
YoY Change	-23.35%	6503.75%	-18.42%
NET CHANGE
Cash From Operating Activities	-$13.10M	-11.88M	-$52.00M
Cash From Investing Activities	-$42.00K	-182.0K	$758.0K
Cash From Financing Activities	$19.05M	5.283M	$31.17M
Net Change In Cash	$5.897M	-6.775M	-$20.11M
YoY Change	-38.16%	-60.24%	-46.41%
FREE CASH FLOW
Cash From Operating Activities	-$13.10M	-$11.88M	-$52.00M
Capital Expenditures	$42.00K	$182.0K	$242.0K
Free Cash Flow	-$13.14M	-$12.06M	-$52.24M
YoY Change	-19.44%	-29.57%	-27.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001624326
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2022	PAVM	Change In Fair Value Derivative Liability ChangeInFairValueDerivativeLiability		usd
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	PAVM	Deemed Dividend On Series Z Warrant Modification DeemedDividendOnSeriesZWarrantModification		usd
CY2023	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend		usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2023	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions		usd
CY2023	PAVM	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2023	PAVM	Incremental Value From Z Warrant Modification IncrementalValueFromZWarrantModification		usd
CY2023	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued		usd
CY2022	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend		usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2022	PAVM	Issue Common Stock Exercise Series Z Warrants Value IssueCommonStockExerciseSeriesZWarrantsValue		usd
CY2022	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions		usd
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets		usd
CY2022	PAVM	Issue Common Stock Vendor Service Agreement IssueCommonStockVendorServiceAgreement		usd
CY2022	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale		usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2022	PAVM	Repayment Of Senior Secured Convertible Note Acceleration Floor Payments RepaymentOfSeniorSecuredConvertibleNoteAccelerationFloorPayments		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	PAVM	Proceeds From Exercise Of Stock Options Issued Under Equity Plan Of Majority Owned Subsidiary ProceedsFromExerciseOfStockOptionsIssuedUnderEquityPlanOfMajorityOwnedSubsidiary		usd
CY2023	PAVM	Purchase Treasury Stock Payment Of Employee Payroll Tax Obligation In Connection With Stockbased Compensation PurchaseTreasuryStockPaymentOfEmployeePayrollTaxObligationInConnectionWithStockbasedCompensation		usd
CY2023Q4	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount		usd
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount		usd
CY2022	PAVM	Issuance Majorityowned Subsidiary Preferred Stock IssuanceMajorityownedSubsidiaryPreferredStock		usd
CY2022	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Three AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueThree		usd
CY2023	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValue		usd
CY2022	PAVM	Issue Common Stock Upon Partial Conversions Of Majority Owned Subsidiary Common Senior Secured Convertible Note IssueCommonStockUponPartialConversionsOfMajorityOwnedSubsidiaryCommonSeniorSecuredConvertibleNote		usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments		pure
CY2022	PAVM	Effective Income Tax Rate Reconciliation Federal Deferred True Up EffectiveIncomeTaxRateReconciliationFederalDeferredTrueUp		pure
CY2022	PAVM	Effective Income Tax Rate Reconciliation State Deferred True Up EffectiveIncomeTaxRateReconciliationStateDeferredTrueUp		pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	PAVM	Deemed Dividend On Series Z Warrant Modification DeemedDividendOnSeriesZWarrantModification		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	38600000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9172331	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	New York, NY
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19639000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39744000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	61000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	278000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	111000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4520000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4054000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	24498000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	43926000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1783000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2451000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4267000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3037000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1424000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3445000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1147000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1121000	usd
CY2023Q4	us-gaap	Assets Assets	33119000	usd
CY2022Q4	us-gaap	Assets Assets	53980000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1786000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2704000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6626000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3705000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1565000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1141000	usd
CY2023Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	44200000	usd
CY2022Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	33650000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	54177000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41200000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2960000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1846000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	57137000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	43046000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	2993000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	2695000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8578505	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6300703	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	237600000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	216195000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-294433000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-228169000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	408000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-53831000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-9681000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	29813000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	20615000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24018000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10934000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33119000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53980000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2452000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	377000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	6420000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3614000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	17583000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	19318000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30947000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41410000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1784000	usd
CY2023	us-gaap	Interest Income Operating InterestIncomeOperating	505000	usd
CY2022	us-gaap	Interest Income Operating InterestIncomeOperating	169000	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	589000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	1281000	usd
CY2023	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	6026000	usd
CY2022	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	1273000	usd
CY2023	PAVM	Loss On Issue And Offering Cost Senior Secured Convertible Note LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote	1186000	usd
CY2022	PAVM	Loss On Issue And Offering Cost Senior Secured Convertible Note LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote	4332000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-3782000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-5434000	usd
CY2023	PAVM	Change In Fair Value Derivative Liability ChangeInFairValueDerivativeLiability	390000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10468000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12151000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79263000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-103238000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-79263000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-103238000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-15088000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14255000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-64175000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-88983000	usd
CY2023	PAVM	Deemed Dividend On Series Z Warrant Modification DeemedDividendOnSeriesZWarrantModification	-1791000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	304000	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	281000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-66270000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-89264000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.16
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.16
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-15.03
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-15.03
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7231546	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7231546	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5938406	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5938406	shares
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-15 reverse stock split
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10934000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1824000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	10002000	usd
CY2023	PAVM	Issue Common Stock Upon Partial Conversions Of Majority Owned Subsidiary Common Senior Secured Convertible Note IssueCommonStockUponPartialConversionsOfMajorityOwnedSubsidiaryCommonSeniorSecuredConvertibleNote	167000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	258000	usd
CY2023	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	551000	usd
CY2023	PAVM	Issuance Majorityowned Subsidiary Common Stock At The Market Facility Net Of Financing Charges IssuanceMajorityownedSubsidiaryCommonStockAtTheMarketFacilityNetOfFinancingCharges	284000	usd
CY2023	PAVM	Issuance Majorityowned Subsidiary Common Stock Settlement Apardx Installment Payment IssuanceMajorityownedSubsidiaryCommonStockSettlementApardxInstallmentPayment	713000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	748000	usd
CY2023	PAVM	Issuance Majorityowned Subsidiary Preferred Stock IssuanceMajorityownedSubsidiaryPreferredStock	18625000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	4255000	usd
CY2023	PAVM	Stockbased Compensation Majorityowned Subsidiary StockbasedCompensationMajorityownedSubsidiary	6884000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-79263000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	79418000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	79418000	usd
CY2022	PAVM	Stock Issued During Period Value Atm Facility StockIssuedDuringPeriodValueATMFacility	79000	usd
CY2022	PAVM	Issue Common Stock Upon Partial Conversions Of Senior Secured Convertible Note IssueCommonStockUponPartialConversionsOfSeniorSecuredConvertibleNote	11807000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	302000	usd
CY2022	PAVM	Adjustment To Additional Paid In Capital Issue Common Stock Of Majorityowned Subsidiary AdjustmentToAdditionalPaidInCapitalIssueCommonStockOfMajorityownedSubsidiary	695000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	358000	usd
CY2022	PAVM	Purchase Majorityowned Subsidiary Common Stock Employee Stock Purchase Plan PurchaseMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan	109000	usd
CY2022	PAVM	Issuance Majorityowned Subsidiary Common Stock Committed Equity Facility Net Of Deferred Financing Charges IssuanceMajorityownedSubsidiaryCommonStockCommittedEquityFacilityNetOfDeferredFinancingCharges	1767000	usd
CY2022	PAVM	Issuance Majorityowned Subsidiary Common Stock Settlement Apardx Installment Payment IssuanceMajorityownedSubsidiaryCommonStockSettlementApardxInstallmentPayment	653000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	5666000	usd
CY2022	PAVM	Stockbased Compensation Majorityowned Subsidiary StockbasedCompensationMajorityownedSubsidiary	13866000	usd
CY2022	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	-548000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-103238000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10934000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-79263000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-103238000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2932000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2457000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	11139000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	19532000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	usd
CY2023	PAVM	Issuance Of Common Stock Installment Settlement Payment IssuanceOfCommonStockInstallmentSettlementPayment	713000	usd
CY2022	PAVM	Issuance Of Common Stock Installment Settlement Payment IssuanceOfCommonStockInstallmentSettlementPayment	653000	usd
CY2023	PAVM	Issue Common Stock Vendor Service Agreement IssueCommonStockVendorServiceAgreement	625000	usd
CY2023	PAVM	Change In Fair Value Senior Secured Convertible Notes ChangeInFairValueSeniorSecuredConvertibleNotes	6026000	usd
CY2022	PAVM	Change In Fair Value Senior Secured Convertible Notes ChangeInFairValueSeniorSecuredConvertibleNotes	1273000	usd
CY2023	PAVM	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote	1111000	usd
CY2022	PAVM	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote	3523000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-3782000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-5434000	usd
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	308000	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	97000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	44000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-183000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	246000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-397000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-918000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-742000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2799000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-554000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52036000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70985000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	242000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1540000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	1000000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	3200000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	758000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4740000	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	18625000	usd
CY2023	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	10000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	35227000	usd
CY2023	PAVM	Repayment Of Senior Secured Convertible Note Acceleration Floor Payments RepaymentOfSeniorSecuredConvertibleNoteAccelerationFloorPayments	79000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1533000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	79000	usd
CY2023	PAVM	Proceeds Majorityowned Subsidiary Common Stock Atthemarket Facility ProceedsMajorityownedSubsidiaryCommonStockAtthemarketFacility	284000	usd
CY2022	PAVM	Proceeds Majorityowned Subsidiary Common Stock Atthemarket Facility ProceedsMajorityownedSubsidiaryCommonStockAtthemarketFacility	1807000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	302000	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	259000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	358000	usd
CY2023	PAVM	Proceeds Majorityowned Subsidiary Common Stock Employee Stock Purchase Plan ProceedsMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan	551000	usd
CY2022	PAVM	Proceeds Majorityowned Subsidiary Common Stock Employee Stock Purchase Plan ProceedsMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan	109000	usd
CY2022	PAVM	Proceeds From Exercise Of Stock Options Issued Under Equity Plan Of Majority Owned Subsidiary ProceedsFromExerciseOfStockOptionsIssuedUnderEquityPlanOfMajorityOwnedSubsidiary	695000	usd
CY2022	PAVM	Purchase Treasury Stock Payment Of Employee Payroll Tax Obligation In Connection With Stockbased Compensation PurchaseTreasuryStockPaymentOfEmployeePayrollTaxObligationInConnectionWithStockbasedCompensation	366000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31173000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38211000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20105000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-37514000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39744000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	77258000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19639000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39744000	usd
CY2023Q4	PAVM	Prepaid Service Providers And Suppliers PrepaidServiceProvidersAndSuppliers	739000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_802_eus-gaap--NatureOfOperations_zI97u6G9uzAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 — <span id="xdx_82E_zGKlqFlASt8">The Company</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description of the Business</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PAVmed is structured to be a multi-product life sciences company organized to advance a pipeline of innovative healthcare technologies. Led by a team of highly skilled personnel with a track record of bringing innovative products to market, PAVmed is focused on innovating, developing, acquiring, and commercializing novel products that target unmet needs with large addressable market opportunities. Leveraging our corporate structure—a parent company that will establish distinct subsidiaries for each financed asset—we have the flexibility to raise capital at the PAVmed level to fund product development, or to structure financing directly into each subsidiary in a manner tailored to the applicable product, the latter of which is our current strategy given prevailing market conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current focus is multi-fold. We continue to pursue commercial expansion and execution of EsoGuard, which is the flagship product of our majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”). In addition, through a separate majority-owned subsidiary, Veris Health (“Veris”), we are focused on entering into strategic partnership opportunities with leading academic oncology systems to expand access to the Veris Platform. In terms of other existing products and technologies, we have adopted an incubator-type platform where we are looking to obtain financing on a product-by-product basis as necessary to advance each asset to a meaningful inflection point along its path to commercialization. Finally, as resources permit, we will continue to explore external innovations that fulfill our project selection criteria without limiting ourselves to any target sector, specialty or condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
CY2023	us-gaap	Revenues Revenues	2500000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-66300000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52000000.0	usd
CY2023Q4	PAVM	Working Capital WorkingCapital	-29700000	usd
CY2023Q4	us-gaap	Cash Cash	19600000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zcg6isQVAPR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zrPsFHaQDah3">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets, inclusive of acquired intangible assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these consolidated financial statements include those related to the estimated fair value of stock-based equity awards, intangible assets, estimated fair value of debt obligations, and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2022Q4	PAVM	Prepaid Service Providers And Suppliers PrepaidServiceProvidersAndSuppliers	599000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	848000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	300000	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	2672000	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	3005000	usd
CY2023Q4	PAVM	Veris Box Supplies VerisBoxSupplies	261000	usd
CY2022Q4	PAVM	Veris Box Supplies VerisBoxSupplies	150000	usd
CY2023Q4	PAVM	Prepaid Expense Deposits And Other Assets Current PrepaidExpenseDepositsAndOtherAssetsCurrent	4520000	usd
CY2022Q4	PAVM	Prepaid Expense Deposits And Other Assets Current PrepaidExpenseDepositsAndOtherAssetsCurrent	4054000	usd
CY2023	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	greater than 50% likelihood
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zO3Yzj8WeoGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_865_zDvxwsrDyate">Reclassifications</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain prior-year amounts have been reclassified to conform to the current year presentation, which includes presenting interest income and classification of certain general and administrative expenses and research and development expenses within operating expenses on the statements of operations, in the consolidated financial statements and accompanying notes to the consolidated financial statements. The impact of the reclassifications made to prior year amounts is not material and did not affect net loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2452000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	377000	usd
CY2023	PAVM	Monthly Fees MonthlyFees	100000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	6420000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3614000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3502000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3259000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1719000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	808000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1783000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2451000	usd
CY2023	us-gaap	Depreciation Depreciation	911000	usd
CY2022	us-gaap	Depreciation Depreciation	673000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1871000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1174000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	89000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	191000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	113000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	52000	usd
CY2023	us-gaap	Lease Cost LeaseCost	2073000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1417000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1854000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	835000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	787000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	617000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	471000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	848000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5412000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	887000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4525000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1563000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1078000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2728000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3949000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M13D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M2D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07875	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07875	pure
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4267000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3037000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4525000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2987000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1565000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1141000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2960000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1846000	usd
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	3200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5375000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5375000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3951000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1930000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1424000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3445000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2021000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1784000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	688000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	421000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	315000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1424000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2507000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1940000	usd
CY2023Q4	PAVM	Amended License Agreement Royalty Fee AmendedLicenseAgreementRoyaltyFee	96000	usd
CY2022Q4	PAVM	Amended License Agreement Royalty Fee AmendedLicenseAgreementRoyaltyFee	10000	usd
CY2023Q4	PAVM	Accrued Operating Expenses AccruedOperatingExpenses	3246000	usd
CY2022Q4	PAVM	Accrued Operating Expenses AccruedOperatingExpenses	1755000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	777000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6626000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3705000	usd
CY2023Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	44200000	usd
CY2022Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	33650000	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	37683000	usd
CY2023Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	44200000	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32747000	usd
CY2022Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	33650000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	33650000	usd
CY2023	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	11111000	usd
CY2023	PAVM	Fair Value Adjustment Issue Date FairValueAdjustmentIssueDate	789000	usd
CY2023	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	6175000	usd
CY2023	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	412000	usd
CY2023	PAVM	Debt Instruments Fair Value DebtInstrumentsFairValue	5237000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	44200000	usd
CY2023	PAVM	Other Income Expense Change In Fair Value OtherIncomeExpenseChangeInFairValue	6026000	usd
CY2022	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	38750000	usd
CY2022	PAVM	Fair Value Adjustment Issue Date FairValueAdjustmentIssueDate	3550000	usd
CY2022	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	6003000	usd
CY2022	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	370000	usd
CY2022	PAVM	Debt Instruments Fair Value DebtInstrumentsFairValue	-2277000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	33650000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	33650000	usd
CY2022	PAVM	Other Income Expense Change In Fair Value OtherIncomeExpenseChangeInFairValue	1273000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	11139000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	19532000	usd
CY2023Q4	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	390000	usd
CY2023	PAVM	Stock Issued During Period Share Atm Facilities StockIssuedDuringPeriodShareATMFacilities	321288	shares
CY2023	PAVM	Stock Issued During Period Value Atm Facilities StockIssuedDuringPeriodValueATMFacilities	1823000	usd
CY2023	PAVM	Payments For Commissions Percentage PaymentsForCommissionsPercentage	0.03	pure
CY2024Q1	PAVM	Stock Issued During Period Share Atm Facilities StockIssuedDuringPeriodShareATMFacilities	133299	shares
CY2024Q1	PAVM	Stock Issued During Period Value Atm Facilities StockIssuedDuringPeriodValueATMFacilities	495000	usd
CY2024Q1	PAVM	Payments For Commissions Percentage PaymentsForCommissionsPercentage	0.03	pure
CY2022Q4	us-gaap	Minority Interest MinorityInterest	20615000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	17752000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-15088000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14255000	usd
CY2023	PAVM	Impact Of Subsidiary Equity Transactions ImpactOfSubsidiaryEquityTransactions	-1983000	usd
CY2022	PAVM	Impact Of Subsidiary Equity Transactions ImpactOfSubsidiaryEquityTransactions	28000	usd
CY2023	PAVM	Issuance Majorityowned Subsidiary Preferred Stock IssuanceMajorityownedSubsidiaryPreferredStock	18625000	usd
CY2023	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value One AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueOne	284000	usd
CY2022	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value One AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueOne	1767000	usd
CY2023	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Two AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueTwo	713000	usd
CY2022	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Two AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueTwo	653000	usd
CY2023	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Three AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueThree	147000	usd
CY2022	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValue	695000	usd
CY2023	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Four AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueFour	551000	usd
CY2022	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Four AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueFour	109000	usd
CY2023	PAVM	Issue Common Stock Upon Partial Conversions Of Majority Owned Subsidiary Common Senior Secured Convertible Note IssueCommonStockUponPartialConversionsOfMajorityOwnedSubsidiaryCommonSeniorSecuredConvertibleNote	167000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5762000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13859000	usd
CY2023	PAVM	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Values AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValues	20000	usd
CY2022	PAVM	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Values AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValues	7000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	29813000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	20615000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-16789000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-24265000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-19323000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	11124000	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-36112000	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-13141000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	36112000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13141000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.061	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.066	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.027	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.010	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.022	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.013	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.152	pure
CY2023	PAVM	Effective Income Tax Rate Reconciliation Federal Deferred True Up EffectiveIncomeTaxRateReconciliationFederalDeferredTrueUp	0.058	pure
CY2023	PAVM	Effective Income Tax Rate Reconciliation State Deferred True Up EffectiveIncomeTaxRateReconciliationStateDeferredTrueUp	0.132	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.456	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.127	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	67786000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	37032000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	537000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	922000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	12304000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11105000	usd
CY2023Q4	PAVM	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1266000	usd
CY2022Q4	PAVM	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	836000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	8234000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6193000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3481000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1719000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	385000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	311000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	17000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	15000	usd
CY2023Q4	PAVM	Deferred Tax Assets Tax Depreciation And Amortization DeferredTaxAssetsTaxDepreciationAndAmortization	800000	usd
CY2022Q4	PAVM	Deferred Tax Assets Tax Depreciation And Amortization DeferredTaxAssetsTaxDepreciationAndAmortization	221000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	94810000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	58354000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1194000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	850000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1194000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	850000	usd
CY2023Q4	PAVM	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	93616000	usd
CY2022Q4	PAVM	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	57504000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	93616000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57504000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	36112000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13141000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	236300000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	158400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	13800000	usd
CY2023	PAVM	Operating Loss Carry Forward Expiration Description OperatingLossCarryForwardExpirationDescription	statutory expiration dates commencing in 2037
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	222500000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	260000000.0	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-79263000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-103238000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-15088000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14255000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-64175000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-88983000	usd
CY2023	PAVM	Deemed Dividend On Series Z Warrant Modification DeemedDividendOnSeriesZWarrantModification	-1791000	usd
CY2023	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-304000	usd
CY2022	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-281000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-66270000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-89264000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7231546	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7231546	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5938406	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5938406	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.16
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.16
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-15.03
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-15.03
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2145830	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1712365	shares

Files In Submission

Name	View Source	Status
0001493152-24-011172-index-headers.html	Edgar Link	pending
0001493152-24-011172-index.html	Edgar Link	pending
0001493152-24-011172.txt	Edgar Link	pending
0001493152-24-011172-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pavm-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
pavm-20231231_cal.xml	Edgar Link	unprocessable
pavm-20231231_def.xml	Edgar Link	unprocessable
pavm-20231231_lab.xml	Edgar Link	unprocessable
pavm-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PAVM
PAVmed Inc. Stock $pavm

2024 Q1 Form 10-K Financial Statement

#000149315224011172 Filed on March 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PAVM PAVmed Inc. Stock $pavm

2024 Q1 Form 10-K Financial Statement

#000149315224011172 Filed on March 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PAVM
PAVmed Inc. Stock $pavm